Ridgeback Biotherapeutics

Last updated

Ridgeback Biotherapeutics is a Miami-based biotechnology company, primarily known for its involvement in developing a successful COVID-19 medication.

Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of S.A.C. Capital Advisors [1] ) and his wife Wendy Holman. Wendy is the CEO at the company, which refers to itself as a majority woman owned business. [2]

In early 2020, Ridgeback purchased an exclusive license for the commercial development of Molnupiravir from Emory University, where the drug was initially developed with $16 million in grants from Federal agencies including the National Institutes of Health. The terms of the deal were undisclosed. Molnupiravir was initially researched as a treatment for influenza, but may have broad spectrum activity against other viruses.

Ridgeback was mentioned in a whistleblower complaint from Rick Bright, former director of the Biomedical Advanced Research and Development Authority. The complaint alleged that Ridgeback lobbied the government for millions in funding to help develop Molnupiravir.

Merck & Co. partnered with Ridgeback to perform clinical trials with Molnupiravir in humans to treat COVID-19. Ridgeback has also developed a number of other advanced medications such as monoclonal antibody Ansuvimab against the Ebola virus. [3] [4] [5] [6] [7] [8] [9] [10]

Related Research Articles

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

<span class="mw-page-title-main">Favipiravir</span> Experimental antiviral drug with potential activity against RNA viruses

Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.

<span class="mw-page-title-main">Galidesivir</span> Antiviral drug

Galidesivir is an antiviral drug, an adenosine analog. It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.

<span class="mw-page-title-main">Ebola virus disease treatment research</span>

There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed. For past and current Ebola epidemics, treatment has been primarily supportive in nature.

<span class="mw-page-title-main">Riamilovir</span> Chemical compound

Riamilovir is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.

<span class="mw-page-title-main">Remdesivir</span> Antiviral drug

Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.

Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Colleen S. Kraft is an infectious disease physician, associate professor in the Department of Pathology and Laboratory Medicine, and the director of the Clinical Virology Research Laboratory at Emory University School of Medicine. In 2014, she led Emory University Hospital's effort to treat and care for Ebola virus disease patients and is currently working to address the COVID-19 pandemic in Georgia. She currently serves on Georgia's COVID-19 task force.

<span class="mw-page-title-main">Molnupiravir</span> Antiviral medication

Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID-19 in those infected by SARS-CoV-2. It is taken by mouth.

<span class="mw-page-title-main">GS-441524</span> Metabolite of remdesivir

GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats, but GS-441524 has been found to be effective treatment for FIP.

<span class="mw-page-title-main">Rick Bright</span> American immunologist and whisteblower

Rick Arthur Bright is an American immunologist, vaccine researcher, and public health official. He was the director of the Biomedical Advanced Research and Development Authority (BARDA) from 2016 to 2020. In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health. On October 6, 2020, Bright resigned from the government. On November 9 he was named a member of President-elect Joe Biden's coronavirus advisory board.

<span class="mw-page-title-main">Sangivamycin</span> Chemical compound

Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.

Although several medications have been approved in different countries as of April 2022, not all countries have these medications. Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir or remdesivir, either of which reduces the risk of serious illness or hospitalization. In the US, the Biden Administration COVID-19 action plan includes the Test to Treat initiative, where people can go to a pharmacy, take a COVID test, and immediately receive free Paxlovid if they test positive.

<span class="mw-page-title-main">Nirmatrelvir</span> COVID-19 antiviral medication

Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.

<span class="mw-page-title-main">Lufotrelvir</span> Chemical compound

Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor. It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.

<span class="mw-page-title-main">Bemnifosbuvir</span> Chemical compound

Bemnifosbuvir is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. Bemnifosbuvir has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages, so the planned Phase 3 trials are being redesigned and results are not expected until late 2022.

<span class="mw-page-title-main">Ensitrelvir</span> COVID-19 SARS-CoV-2 3CL-protease-inhibitor antiviral drug

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.

<span class="mw-page-title-main">PANORAMIC trial</span> Clinical trial of antivirals for COVID-19 infection

The Platform Adaptive Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community is a clinical trial in the United Kingdom to test the effectiveness of new antiviral drugs at the early stages of COVID-19 infections. The study aims to find out if antivirals can prevent the need for hospitalisation and help faster recovery for people aged over 50 and those at higher risk due to underlying health conditions. PANORAMIC is sponsored by the University of Oxford and funded by the National Institute for Health and Care Research (NIHR). The trial was launched in December 2021, and as of June 2022, over 25,000 people are enrolled as participants.

References

  1. ↑ Crow, David (30 June 2020). "Hedge fund manager stands to profit on 'flip' of taxpayer-funded coronavirus drug". Financial Times . Retrieved 1 December 2021.
  2. ↑ "Breakthrough Ebola Treatment Receives Contract from U.S. Government" (Press release). Ridgeback Biotherapeutics. 2 April 2020. Retrieved 2021-12-01.
  3. ↑ "Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels". Emory University. March 17, 2021. Retrieved 2021-11-07.
  4. ↑ Lee, Arnold (2021). "Ansuvimab: First Approval". Drugs. 81 (5): 595–598. doi:10.1007/s40265-021-01483-4. PMC   7983082 . PMID   33751449.
  5. ↑ Painter, George R.; Natchus, Michael G.; Cohen, Oren; Holman, Wendy; Painter, Wendy P. (2021). "Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19". Current Opinion in Virology. 50: 17–22. doi:10.1016/j.coviro.2021.06.003. PMC   8277160 . PMID   34271264.
  6. ↑ Imran, Mohd.; Kumar Arora, Mandeep; Asdaq, Syed Mohammed Basheeruddin; Khan, Shah Alam; Alaqel, Saleh I.; Alshammari, Mohammed Kanan; Alshehri, Mohammed M.; Alshrari, Ahmed Subeh; Mateq Ali, Alreshidi; Al-Shammeri, Ahmed Muteb; Alhazmi, Bushra Dhuhayyan; Harshan, Aishah Ali; Alam, Md. Tauquir; Abida, Abida (2021). "Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19". Molecules. 26 (19): 5795. doi: 10.3390/molecules26195795 . PMC   8510125 . PMID   34641339.
  7. ↑ Fischer, William; Eron, Joseph J.; Holman, Wayne; Cohen, Myron S.; Fang, Lei; Szewczyk, Laura J.; Sheahan, Timothy P.; Baric, Ralph; Mollan, Katie R.; Wolfe, Cameron R.; Duke, Elizabeth R.; Azizad, Masoud M.; Borroto-Esoda, Katyna; Wohl, David A.; Loftis, Amy James; Alabanza, Paul; Lipansky, Felicia; Painter, Wendy P. (2021). "Molnupiravir, an Oral Antiviral Treatment for COVID-19". medRxiv   10.1101/2021.06.17.21258639v1 .
  8. ↑ Ledford, Heidi (10 November 2021). "COVID antiviral pills: what scientists still want to know". Nature . doi:10.1038/d41586-021-02783-1. PMID   34625735. S2CID   238529450 . Retrieved 1 December 2021.
  9. ↑ Rowland, Christopher (25 June 2020). "Hedge fund manager stands to profit on 'flip' of taxpayer-funded coronavirus drug". Washington Post . Retrieved 1 December 2021.
  10. ↑ "Emory's DRIVE, Ridgeback partnering for drug vs coronavirus" (Press release). Emory University. 23 March 2020. Retrieved 2021-12-01.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.